NAOV 財務： ENvue Medical, Inc. AI 分析

首頁

股票

NAOV

財務狀況

NAOV 財務

ENvue Medical, Inc.

0%

$0

截至今日：Mar 26, 13:05:02 GMT-4

概觀預測收益股利財務狀況

關鍵數據

前收市價

開盤價

當日範圍

52週區間

交易量

平均成交量

股息收益率

每股盈餘 (TTM)

市值

什麼是 NanoVibronix, Inc.？

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Tyler, Texas and currently employs 15 full-time employees. The company went IPO on 2015-04-24. The firm focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.

功能特性

資源

市場

收入

資產負債表

現金流量

年度

每季

NAOV 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
營收	0	0	8	12	7	33
營收年增率 (YoY)	-100%	-100%	-33%	71%	-79%	-85%
營收成本	--	--	--	--	--	--
毛利	--	--	--	--	--	--
銷售、一般及管理費用	13	13	31	28	18	17
研發	--	--	--	29	26	16
營業費用	28	28	55	69	57	41
其他非營業收入 (費用)	0	-2	0	0	0	0
稅前淨利	-17	-17	-45	-44	-50	-11
所得稅費用	-5	-5	-6	-8	-8	-1
淨利	-12	-12	-38	-35	-42	-9
淨利成長	-68%	-68%	9%	-17%	367%	-106%
稀釋後流通股數	326.54	306	326.54	300.52	290.11	286.34
股數年變動 (YoY)	-5%	-6%	9%	4%	1%	-3%
每股盈餘 (稀釋)	-0.03	-0.04	-0.11	-0.11	-0.14	-0.03
每股盈餘成長率	-69%	-66%	2%	-21%	348%	-107%
自由現金流	-29	-29	-51	-98	-23	0
每股自由現金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
營業利益率	0%	0%	-587.5%	-466.66%	-714.28%	-21.21%
淨利率	0%	0%	-475%	-291.66%	-600%	-27.27%
自由現金流利潤率	0%	0%	-637.5%	-816.66%	-328.57%	0%
EBITDA	-26	-26	-45	-54	-49	-7
EBITDA 利潤率	0%	0%	-562.5%	-450%	-700%	-21.21%
EBITDA 中的折舊與攤銷	2	2	2	2	1	0
EBIT	-28	-28	-47	-56	-50	-7
EBIT 利潤率	0%	0%	-587.5%	-466.66%	-714.28%	-21.21%
有效稅率	29.41%	29.41%	13.33%	18.18%	16%	9.09%

Follow-Up Questions

ENvue Medical, Inc. 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），Nykode Therapeutics AS 的總資產為 $99，淨isProfitable}為 $-12

NAOV 的關鍵財務比率是什麼？



Nykode Therapeutics AS 的流動比率為 12.37，淨利潤率為 0，每股銷售為 $0。

ENvue Medical, Inc. 的收入按細分市場或地理位置如何劃分？



Nykode Therapeutics AS 最大收入來源為 Novel Vaccines and Immunotherapies，在最近的收益報告中收入為 136,380,103。就地區而言，United States 是 Nykode Therapeutics AS 的主要市場，收入為 136,380,103。

ENvue Medical, Inc. 是否盈利？



無，根據最新的財務報表，Nykode Therapeutics AS 的淨損失為 $-12

ENvue Medical, Inc. 有負債嗎？



是的，Nykode Therapeutics AS 的負債為 8

ENvue Medical, Inc. 的流通股有多少？



Nykode Therapeutics AS 的總流通股為 326.54

ENvue Medical, Inc. (NAOV) 財務

NAOV 股價走勢圖